Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  JAMA Internal Medicine

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamainternmed.2014.6936PMID 25561419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Antidiabetic Drugs in the U.S., 2003–2012

  2014cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

  2011cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper

• Triple oral therapy with metformin, DPP‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)

  2025cites this paper
• Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study

  2022cites this paper
• A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan

  2021cites this paper
• Effect of Metformin Hydrochloride Administration and itsWithdrawal on the Kidneys of Adult Male Albino Rats:Histological and Biochemical Studies

  2021cites this paper
• The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.

  2020cites this paper
• Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas

  2020cites this paper
• Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.

  2019cites this paper
• Medications

  2019cites this paper
• Overcoming barriers to the use of metformin: patient and provider perspectives

  2019cites this paper
• Metformin Lactic Acidosis: should we still be afraid?

  2019cites this paper
• Overcoming barriers to the use of metformin: patient and provider perspectives

  2019cites this paper
• Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study

  2018cites this paper
• Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease

  2018cites this paper
• Identifying prevalence and risk factors for metformin non-persistence: a retrospective cohort study using an electronic health record

  2018cites this paper
• Klinische Bedeutung von HbA1c-Schwellenwerten und Diabetes im Hinblick aufkardiovaskuläre Ereignisse und Tod im hohen Alter

  2018cites this paper
• Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.

  2017cites this paper
• Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors

  2017cites this paper
• Metformin and Chronic Renal Disease: Proposal for a “Territorial” Therapeutic Diagnostic Path

  2017influential citation
• Lactate Levels with Chronic Metformin Use: A Narrative Review

  2017cites this paper
• Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy.

  2017cites this paper
• Nephroprotective Effects of Metformin in Diabetic Nephropathy

  2017cites this paper
• Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease

  2017cites this paper
• Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes

  2017cites this paper
• A retrospective cohort analysis of hypoglycaemic and cardiovascular agent use in young adults in the Irish primary care setting

  2017cites this paper
• Recommendations for care of patients with diabetes and kidney impairment

  2016cites this paper
• Usage of metformin in patients with type 2 diabetes mellitus

  2016cites this paper
• Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity

  2016cites this paper
• Metformin: From Research to Clinical Practice.

  2016cites this paper
• Lactic acidosis and the relationship with metformin usage

  2016cites this paper
• Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort

  2016cites this paper
• Poučení k terapii diabetes mellitus

  2016cites this paper
• INTRAVENOUS CONTRAST IN PATIENTS WITH DIABETES ON METFORMIN: NEW COMMON SENSE GUIDELINES.

  2016cites this paper
• Case–control study of oral glucose‐lowering drugs in combination with long‐acting insulin and the risks of incident myocardial infarction and incident stroke

  2016cites this paper
• Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe

  2016cites this paper
• Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

  2015cites this paper
• Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

  2015cites this paper
• Mortality and metformin use in patients with advanced chronic kidney disease--Authors' reply.

  2015cites this paper
• Using metformin in the presence of renal disease

  2015cites this paper
• Mortality and metformin use in patients with advanced chronic kidney disease.

  2015cites this paper